Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol®

PHASE3CompletedINTERVENTIONAL
Enrollment

1,565

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

July 31, 2008

Study Completion Date

September 30, 2008

Conditions
Pregnancy
Interventions
DRUG

C31G

The subject will insert one applicator of C31G prior to each episode of vaginal intercourse during her participation in the study.

DRUG

nonoxynol-9 (N-9)

The subject will insert one applicator of Conceptrol® vaginal gel (nonoxynol-9) prior to each episode of vaginal intercourse during her participation in the study.

Trial Locations (15)

10016

New York University, New York

10032

Columbia University, New York

15213

University of Pittsburgh, Pittsburgh

19104

University of Pennsylvania Medical Center, Philadelphia

21224

Johns Hopkins Bayview Medical Center, Baltimore

23507

Jones Institute of Reproductive Medicine, EVMS, Norfolk

43210

The Ohio State University College of Medicine, Columbus

44106

University Hospitals of Cleveland MacDonald Women's Hospital, Cleveland

45267

University of Cincinnati, Cincinnati

75390

U.T. Southwestern Medical Center, Dallas

80010

University of Colorado - Advanced reproductive Medicine, Aurora

90010

California Family Health Council, Los Angeles

94710

California Family Health Council, Berkeley

97239

Oregon Health & Science University, Portland

01199

Bay State Medical Center, Springfield

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Premier Research

OTHER